Copyright
©The Author(s) 2016.
World J Gastroenterol. Jul 21, 2016; 22(27): 6246-6256
Published online Jul 21, 2016. doi: 10.3748/wjg.v22.i27.6246
Published online Jul 21, 2016. doi: 10.3748/wjg.v22.i27.6246
Table 1 Antibodies and immunohistochemistry parameters used in this study
Antibody | Manufacturer | Clone | Species | Dilution | Retrieval1 | Positive control | Staining pattern |
EGFR PharmDx | Dako | 2-18C9 | Mouse | Pre-diluted | Proteinase K | Provided by manufacturer | Membrane |
Ki67 Ag | Dako | MIB-1 | Mouse | 1:400 | Standard | Tonsil | Nucleus |
Caspase 3 | DBS | 3C SP03 | Mouse | 1:400 | Standard | Tonsil/stomach | Cytoplasm |
ERK1 | DBS | Polyclonal | Rabbit | 1:100 | Standard | Breast carcinoma | Cytoplasm |
ERK2 | DBS | Polyclonal | Rabbit | 1:400 | Standard | Breast carcinoma | Cytoplasm |
MET | Cell signaling | Polyclonal | Rabbit | 1:50 | Standard | Breast carcinoma | Cytoplasm |
mTOR | Cell signaling | Polyclonal | Rabbit | 1:50 | Standard | Lymphoid tissue | Cytoplasm |
K19 | Novocastra | b170 | Mouse | 1:300 | Standard | Cholangio-carcinoma | Cytoplasm |
Vimentin | Dako | Vim3B4 | Mouse | 1:3000 | Standard | Kidney | Cytoplasm |
p53 | Dako | DO7 | Mouse | 1:100 | Standard | Breast carcinoma | Nucleus |
Beta-catenin | BD | 14Beta-catenin | Mouse | 1:800 | Standard | Tonsil | Membrane/nucleus |
Cyclin D1 | Dako | SP4 | Rabbit | 1:100 | Steamer 10 mmol/L TRIS, 1 mmol/L EDTA, pH 9 | Tonsil/intestine | Nucleus |
Table 2 Clinicopathological features of 80 hepatocellular carcinoma autopsy cases
Feature | n (%) |
Sex | |
Male | 62 (77.5) |
Female | 18 (22.5) |
Age, yr | |
Median | 59.5 |
Range | 28-82 |
With cirrhotic liver | 72 (90.0) |
With incidental small HCC, < 2.0 cm | 4 (5.0) |
Etiology | |
HCV only | 27 (33.7) |
HCV + alcohol | 9 (11.2) |
HCV + HBV | 2 (2.5) |
HCV + HBV + alcohol | 1 (1.3) |
Alcohol only | 11 (13.8) |
HBV only | 9 (11.2) |
HBV + alcohol | 3 (3.8) |
Hemochromatosis | 2 (2.5) |
Cryptogenic | 10 (12.5) |
Data not available | 6 (7.5) |
Larger tumor size, cm | |
Median | 4 |
Range | 0.8-18.0 |
Non-available/non-sizable cases | 22 (27.5) |
Number of tumor nodules | |
1 | 24 (33.3) |
2 | 4 (5.6) |
3 | 1 (1.4) |
≥ 4 | 43 (53.8) |
Non-available/uncountable cases | 8 (10.0) |
Gross pattern | |
Nodular | 31 (38.8) |
Massive with satellite lesions | 25 (31.3) |
Diffuse | 8 (10.0) |
Non-available/non-sizable cases | 11 (13.8) |
Histological grade, Edmondson-Steiner grade | |
1 + 2 | 22 (27.5) |
3 | 47 (58.8) |
4 | 11 (13.8) |
Predominant histological pattern or variant | |
Trabecular | 36 (45.0) |
Acinar/pseudoacinar | 9 (11.2) |
Solid/macrotrabecular | 24 (30.0) |
Mixed | 9 (11.2) |
Clear cell | 2 (2.5) |
Table 3 Dissemination in 80 hepatocellular carcinoma autopsy cases
Metastasis feature | n (%) |
Large vein invasion | 12 (15.0) |
Extrahepatic metastases | 30 (37.5) |
Extrahepatic metastases sites, cases by site | |
Lungs | 21 (26.3) |
Lymph node | 6 (7.5) |
Adrenal, bone, spleen, diaphragm, peritoneum | 2 (2.5) |
Small bowel, bladder, colon, pancreas, pituitaries, thyroid, pleura | 1 (1.3) |
Table 4 Overall expression and cut-off points for immunohistochemical markers in non-neoplastic liver, primary hepatocellular carcinoma and metastases n (%)
IHC marker | Cut-off | Non-neoplastic | Primary HCC | Metastases | P value |
26 cases | 75 cases | 17 cases | |||
EGFR overexpression | ≥ 200/3001 | 17 (65) | 29 (39) | 6 (38)2 | 0.054 |
Ki67 | ≥ 0.1% | 2 (8)a | 45 (63)4 | 13 (76) | < 0.001a |
K19 | > 1% | 0 (0)a | 12 (16)3 | 5 (29) | 0.011a |
Vimentin | > 0/300 | 0 (0) | 4 (6)3 | 3 (18) | 0.064 |
Caspase 3 loss | ≤ 10/300 | 2 (8)a | 26 (36)3 | 7 (41) | 0.009a |
Cyclin D1 | > 0.1% | 4 (15) | 16 (23)5 | 9 (53)a | 0.018a |
mTOR expression | ≥ 100/3001 | 8 (31) | 14 (21)5 | 5 (31)2 | 0.533 |
MET expression | ≥ 100/3001 | 10 (38) | 12 (17)4 | 5 (29) | 0.068 |
ERK1 overexpression | ≥ 200/3001 | 0 (0)a | 10 (14)4 | 5 (33)3 | 0.006a |
ERK2 overexpression | ≥ 200/3001 | 0 (0)a | 10 (14)4 | 4 (24) | 0.029a |
p53 | ≥ 10% | 2 (8)a | 28 (42)5 | 8 (50)2 | 0.002a |
Beta-catenin, membrane | ≥ 100/3001 | 10 (38) | 42 (61)5 | 11 (65) | 0.113 |
Beta-catenin, nucleus | 2 or 3+ | 0 (0) | 9 (9)5 | 3 (18) | 0.070 |
Table 5 Expression of immunohistochemical markers in categories of histological grade for primary hepatocellular carcinoma cases n (%)
IHC marker | Cut-off | Cases/valid samples | P value | ||
Grades 1 + 2 | Grade 3 | Grade 4 | |||
EGFR overexpression | ≥ 200/3001 | 14 (67)a | 12 (27) | 3 (30) | 0.008a |
Ki67 | ≥ 0.1% | 6 (30)a | 31 (74) | 8 (80) | 0.002a |
K19 | > 1% | 0 (0) | 7 (17) | 5 (45)a | 0.005a |
Vimentin | > 0/300 | 0 (0) | 3 (7) | 1 (9) | 0.465 |
Caspase 3 loss | ≤ 10/300 | 3 (15) | 16 (38) | 8 (73)a | 0.006a |
Cyclin D1 | > 0.1% | 4 (20) | 9 (21) | 3 (30) | 0.847 |
mTOR expression | ≥ 100/3001 | 7 (37) | 17 (45) | 1 (10) | 0.134 |
MET expression | ≥ 100/3001 | 8 (42)a | 6 (14) | 0 (0) | 0.012a |
ERK1 overexpression | ≥ 200/3001 | 0 (0) | 8 (20) | 2 (18) | 0.081 |
ERK2 overexpression | ≥ 200/3001 | 1 (5) | 6 (14) | 3 (30) | 0.148 |
p53 | ≥ 10% | 5 (28) | 16 (42) | 7 (64) | 0.164 |
Beta-catenin, membrane | ≥ 100/3001 | 13 (65) | 25 (64) | 4 (40) | 0.343 |
Beta-catenin, nucleus | 2 or 3+ | 0 (0) | 1 (3) | 1 (10) | 0.352 |
Table 6 General correlation between expression scores for immunohistochemical markers and categories of histological grade for primary hepatocellular carcinoma
Grade | Ki67 | K19 | p53 | ERK1 | BcatN | ERK2 | Vim | CKD1 | BcatM | mTOR | MET | EGFR | Group No. | |
Ki67 | 0.43a | Group 1 | ||||||||||||
K19 | 0.37b | 0.03 | ||||||||||||
p53 | 0.36c | 0.29d | 0.08 | |||||||||||
ERK1 | 0.34c | 0.39b | 0.37b | 0.17 | ||||||||||
BcatN | 0.23 | 0.44a | 0.13 | 0.24 | 0.18 | |||||||||
ERK2 | 0.19 | 0.63a | 0.22 | -0.10 | 0.36c | 0.24 | ||||||||
Vim | 0.14 | 0.11 | 0.51a | 0.02 | 0.31c | 0.08 | 0.14 | |||||||
CKD1 | 0.03 | 0.46a | -0.32c | -0.10 | 0.03 | 0.26d | 0.29d | -0.19 | Group 2 | |||||
BcatM | -0.08 | 0.26d | -0.01 | -0.23 | 0.17 | -0.07 | 0.42a | 0.01 | 0.25d | |||||
mTOR | -0.24d | -0.02 | -0.20 | -0.21 | 0.25d | -0.03 | 0.13 | -0.13 | 0.17 | 0.44a | ||||
MET | -0.32c | 0.16 | -0.20 | -0.35c | -0.01 | 0.22 | 0.39b | -0.18 | 0.38b | 0.18 | 0.40b | |||
EGFR | -0.34c | 0.00 | -0.14 | -0.13 | -0.04 | -0.24 | 0.22 | -0.07 | 0.13 | 0.20 | 0.11 | 0.23 | Group 3 | |
Casp3 | -0.42a | -0.18 | -0.25d | -0.46a | -0.19 | -0.06 | 0.06 | -0.27d | 0.19 | 0.16 | 0.32b | 0.41a | 0.35c |
- Citation: Felipe-Silva A, Wakamatsu A, dos Santos Cirqueira C, Alves VAF. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases. World J Gastroenterol 2016; 22(27): 6246-6256
- URL: https://www.wjgnet.com/1007-9327/full/v22/i27/6246.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i27.6246